We are i&i Prague, a bio-innovation center located right in the heart of Europe. Our objective is to identify the potential of new inventions in Drug Discovery, Diagnostics, MedTech and other Life Science fields. We do this by scouting for innovative projects and investing in the most promising ones. Then we will help with product development and, ultimately, market entry.
We can help you with
Dec 23, 2022
We are looking for new Antonin Holy and new drugs and diagnostics that can have a global impact and success
"i&i Bio invests in technology transfer with a strong focus on healthcare. We look for unique technologies that come from Czech and foreign science. We always try to find something new and unique, something that could bring great benefit to patients and also to our investors," says Jaromír Zahrádka for Fintag.cz. The podcast is in the Czech language.
Sep 28, 2022
Smart bandages not only capture pathogens, but also destroy them in no time. All they need is ordinary light.
Hospital-acquired infections are a problem that current technologies are not able to deal with effectively. However, this could change in the future; the Czech spin-off LAM-X a.s. is working on the development of a nanomaterial that not only passively prevents pathogens from entering open wounds, but can also actively destroy them...
Sep 13, 2022
CasInvent Pharma Raises €1.3 Million from KHAN-I and i&i Biotech Fund
CasInvent Pharma, an early-stage drug discovery company developing small-molecule compounds with anticancer properties, has raised an investment round of €1.3 million provided by KHAN-I and i&i Bio. With this funding, CasInvent will be strengthening its portfolio of CK inhibitors and progressing its lead compound to...
i&i Prague in numbers
We have created or otherwise supported 15 spin-off companies from 5 countries.
We have an equity stake in 9 spin-offs. We have already announced our first exit.
Overall, the spin-offs in our portfolio have raised more than CZK 1.8 billion from other investors.
We have participatedin the sale of more than 10 licenses with a value exceeding CZK 5 million.